A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

Trial Details

NCT ID

NCT07223047

Phase

PHASE1 / PHASE2

Sponsor

Bristol-Myers Squibb

Status

RECRUITING

Cancer Type

Non-Small Cell (NSCLC) Lung Cancer

Interventions

• BMS-986523
• Gemcitabine
• Nab-Paclitaxel
• Cetuximab
• Pembrolizumab

Locations (sample)

• Baltimore, Maryland, United States|39.29038,-76.61219
• San Antonio, Texas, United States|29.42412,-98.49363
• West Valley City, Utah, United States|40.69161,-112.00105
• Fairfax, Virginia, United States|38.84622,-77.30637
• Vancouver, British Columbia, Canada|49.24966,-123.11934

Key Eligibility Criteria

• Participants must have a histologically confirmed diagnosis of a locally advanced and unresectable or metastatic solid tumor malignancy with a know…
• Participants must, for Arm D, have a PD-L1 expression (≥50%).
• Participants must have previously received, be ineligible for, or decline (after having been provided adequate information to make an informed deci…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.